GSK2008607

CAS No. 1244644-50-5

GSK2008607( —— )

Catalog No. M34270 CAS No. 1244644-50-5

GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 532 Get Quote
5MG 787 Get Quote
10MG 1074 Get Quote
25MG 1463 Get Quote
50MG 1822 Get Quote
100MG 2250 Get Quote
500MG 4410 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    GSK2008607
  • Note
    Research use only, not for human use.
  • Brief Description
    GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.
  • Description
    GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    Raf
  • Recptor
    Raf
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1244644-50-5
  • Formula Weight
    667.72
  • Molecular Formula
    C31H28F3N7O3S2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C)(C)C=1SC(=C(N1)C2=C(F)C(NS(=O)(=O)C3=C(F)C=CC=C3F)=CC=C2)C4=NC(NC=5C=CC(=NC5)N6CCOCC6)=NC=C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • AZ 628

    AZ 628(AZ-628, AZ628)?is a potent and selective B-Raf inhibitor with IC50s of 2.14 uM and 0.19 uM for wt Braf and Braf V600E respectively.

  • Sorafenib

    A potent, orally available Raf inhibitor with IC50 of 6, 22, and 38 nM for Raf-1, wt Braf, and BRaf V599E, respectively.

  • Lonafarnib

    Lonafarnib is an orally bioavailable FPTase inhibitor for H-ras, K-ras-4B and N-ras with IC50 of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Phase 3.